New Trends Affecting the Clinical Trials Industry

18 December 2019
Pharma

As more and more drug manufacturers and biosimilar companies expand their offerings, so too does the need for effective clinical trials, making the clinical trial industry one of today’s fastest-growing sectors. However, making long-term decisions for your business might be tough without a bit of expert advice at your disposal. That’s why Visiongain has highlighted below some important issues to keep an eye on.

Here, you’ll find some of the new trends and restraints affecting the clinical trial industry these days.

Blockchain for Clinical Trials

The Institute of Electrical and Electronics Engineers (IEEE), the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity, recently announced exciting news regarding clinical trials. To increase efficiency and make remote researching easier, they’ve created a new initiative incorporating Internet-of-Things (IoT) technology, artificial intelligence, virtual reality, and blockchain solutions to streamline processes.

The organization cited several reasons for the new initiative, including some of the challenges the clinic trial industry faces, such as regulatory policies and rising costs, patient recruitment and retention, and more.

Small & Medium-Sized Biotechs Facing Huge Challenges

One of the major trends affecting small-to-medium businesses (SMBs) in the biotech industry are the growing intricacies involved with new drug creation and discovery, as well as rising financial costs. This is especially true for smaller manufacturers or startups, where the in-house resources and research tools required to compete in the larger marketplace are virtually non-existent.

However, SMBs in the biotech industry will find some solutions to their problems in the form of contract research organizations (CROs), especially where clinical trials are concerned. SMBs can employ CROs to handle every aspect of the process, from the research and development phase all the way through the execution of clinical trials.

Although CROs will complete much of the necessary processes and duties early on, it’s still essential for SMBs to select a vendor that they can have the final say with. This will help ensure all national and global policies and requirements are met. To do so, employing a reliable vendor management platform is important and will provide all the necessary oversight for outsourced tasks and applications.

Contact Visiongain today for more clinical trial industry info!

If you own or operate an SMB involved in the clinical trial industry, partnering with CROs or outsourcing some tasks early on can help you generate the success needed to carve out a niche in the industry over the long term. Contact the team of experts from Visiongain today by calling +44 (0) 20 7549 9987 or visit our website for more about our in-depth market forecasts and reports.

Recent News

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

Read

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever